amivantamab (Rybrevant)
Jump to navigation
Jump to search
Indications
- non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation(s)
Dosage
- 1050 mg if < 80 kg
- 1400 mg if > 80 kg
Adverse effects
- rash (86%)
- infusion-related reactions (66%)
- paronychia (45%), nail dystrophy, onycholysis[3]
- stomatitis (21%)
- pruritus (17%)
- diarrhea (12%)
* No treatment-related deaths
* adverse events leading to dose reductions (13%) & discontinuation (4%)
* discontinue if symptoms of interstitial lung disease
* limit sun exposure during treatment & for 2 months after treatment
* amivantamab may cause problems with vision.
Laboratory
More general terms
References
- ↑ Mulcahy N FDA OKs First Targeted Therapy for Subset of Patients With NSCLC Medscape - May 21, 2021. https://www.medscape.com/viewarticle/951644
- ↑ Kuehn BM New Targeted Non-Small Cell Lung Cancer Therapy Approved. JAMA. 2021;326(1):20. July 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34228082 https://jamanetwork.com/journals/jama/fullarticle/2781663
- ↑ 3.0 3.1 3.2 3.3 Belzer A, Nguyen MO, Talsania A et al. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatol. Published online November 23, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36416832 https://jamanetwork.com/journals/jamadermatology/fullarticle/2798498